Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
3 , a011684 (2013)
2,3-Bisphosphoglycerate (2,3-BPG) is an intermediate metabolite present in high concentrations in RBCs (approximately 5 mM) and is the principal allosteric effector for hemoglobin (that is present at almost the same concentration as a tetramer), decreasing its affinity for oxygen
In January 2025, the FDA approved semaglutide for kidney disease risk reduction in type 2 diabetes patients with CKD, and in late 2025 approved oral Wegovy (semaglutide 25 mg tablet) as the first GLP-1 pill for weight management ( [19] )
Moderate interaction risk may exist with chemotherapy medicines, because antioxidants may affect how some cancer treatments work
US$ 29.69
US$ 22.40
US$ 21.28
US$ 24.29
US$ 26.75
US$ 26.91
US$ 27.30
US$ 26.52
US$ 29.90
US$ 24.40
